Website Search
ID 16108

A better way to treat cancer, Brian Druker

Interviewee: Brian Druker. Brian Druker talks bout a better way to treat cancer.
But it always seemed to me that you were using very harsh chemicals to cure a disease and that was fantastic but it still seemed there had to be a better way and the better way was to understand what was driving the growth of these cancer cells and if we could get to that point maybe we could treat this disease more rationally. And I always figured wouldn't it be great just to be a part of that discovery that was likely to occur over the next 20 or 30 years.
cancer cells,harsh chemicals,cancer drug,gleevec,brian druker,discovery
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
16109. Sense of urgency, Brian Druker
Brian Druker talks about sense of urgency.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15714. Brian Druker
Brian Druker is a professor at Oregon Health Sciences University.
15058. The first clinical success with Gleevec, Brian Druker
Brian Druker talks about Bud, the first patient restored to health by Gleevec™.
1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving